Project Grant R01HL176663
Award Date 8/1/25
Completion Date 5/31/29
Dollars Obligated $834K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $865,286 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a high-resolution spatiotemporal lineage map of cardiac development. The research aims to spatiotemporally map early cardiac progenitor lineages and their clonal relationships, map the phylogeny of major myocardial cell...
- This Project Grant award, in the amount of $746,800.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at Baylor College of Medicine to investigate the major signaling mechanism controlling spontaneous cardiomyocyte (heart cell) proliferation in the neonatal stage. The research aims to elucidate the role of the CD36 receptor in regulating heart cell regeneration, with a...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $361,083 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, OH. The grant supports research on how acetylation regulates the subcellular localization of the transcription factor YAP and its role in cardiac regeneration. The 5-year project aims to investigate how metabolic stresses affect YAP acetylation through the NAD+/SIRT1/2 axis, and whether...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $693,261 to Baylor College of Medicine to investigate the Hippo-YAP signaling pathway and its role in cardiac regenerative repair. The key objectives are to gain insights into gene therapy strategies that knock down Hippo signaling in cardiac tissue following myocardial infarction, with the goal of improving cardiac function in mouse models of ischemic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
- This Project Grant award of $1,290,338 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research conducted by Jaan Biotherapeutics, Inc. to develop a gene therapy treatment for heart muscle regeneration after myocardial infarction. The research aims to inhibit four specific microRNAs that regulate cardiomyocyte dedifferentiation, proliferation, and redifferentiation, with the goal of stimulating endogenous heart muscle regeneration and...
- This Project Grant award of $601,507, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to elucidate the molecular mechanisms regulating the dynamic nature and interplay between myocardial cell-cell and cell-extracellular matrix (ECM) interactions and the downstream signals that control cardiomyocyte proliferation. The award supports research conducted by Rhode Island Hospital, a division of Lifespan Corporation, to determine the...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $267,000.00 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for a project titled "Multimodal Characterization of Cardiac-Neurodevelopmental Genes." The project aims to (1) identify mechanisms by which certain genetic syndromes lead to alterations in both heart and brain development,...